… This study concluded that erlotinib in combination with … In a Phase II trial, celecoxib was
combined with carboplatin … 13 randomized Phase III clinical trials where the biological …

… phase II trial that combined apricoxib (a COX-2 inhibitor that is similar to celecoxib) and
erlotinib in patients with recurrent non–small… article2 that the celecoxib dose may be inadequate …

… clinical trials of targeted agents in non-small cell lung cancer (… phase II trial is planned
comparing erlotinib plus celecoxib … , and optimal biological dose in patients with advanced solid …

… valuable information about the biology of lung cancer. Outside of … phase I-II study is exploring
the combination of erlotinib and … , in a randomized phase II trial comparing celecoxib with or …

… on how these mutations affect the biology of lung cancer, it is possible that we may be … study
(1) erlotinib plus chemotherapy in combination with radiation and (2) erlotinib plus celecoxib…

… of C225 and low-dose celecoxib may result in a more … determine the levels of PGE 2 in
CAL-27 and Fadu cells treated with … and erlotinib) for NSCLC and head and neck cancer [35], [36]…

… Celecoxib optimal biological dose 600 mg bid (maximal urinary decrease of PGE-M without
toxicity) + Erlotinib … ICH determination of RRM1 protein (involved in nucleotide excision repair…

… aimed at determining the biologically-optimal dose may be … NSCLC combining erlotinib
with polychemotherapy (carboplatin … of a phase II trial of docetaxel plus celecoxib in pretreated …

… An increased understanding of the biology of lung cancer has … , gefitinib and erlotinib were
combined with chemotherapy early in … administered with the COX-2 inhibitor celecoxib (22). A …

… survival, 6.37 months for erlotinib arm versus 5.91 months for … phase II study evaluated
clinical activity of a combination of … In a phase I trial, in patients with non–small-cell lung cancer, …